Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. is an Israeli medical technology company dedicated to the research, development, and commercialization of targeted alpha-radiation therapies for solid tumors. Founded in 2016, the company's mission is to deliver its innovative Alpha DaRT technology to cancer patients globally. Its principal executive offices are located in Jerusalem, Israel.

The core of Alpha Tau's product portfolio is Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). This proprietary technology utilizes short-lived radioactive isotopes, specifically Radium-224, which are delivered directly into tumors. These isotopes release high-energy alpha particles designed to destroy cancer cells effectively while minimizing damage to surrounding healthy tissue. Alpha DaRT is currently undergoing clinical evaluation for a range of solid tumor indications, including head and neck, pancreatic, skin, brain, liver, lung, and prostate cancers.

As a clinical-stage oncology therapeutics company, Alpha Tau Medical has achieved notable milestones, including receiving marketing approval for Alpha DaRT in Japan for unresectable locally advanced or recurrent head and neck cancer in February 2026. The company has also announced upcoming presentations of pancreatic cancer data at major medical conferences in 2026 and secured FDA approval for an Investigational Device Exemption (IDE) supplement to expand its Alpha DaRT IMPACT trial for pancreatic cancer. Uzi Sofer serves as the CEO and Chairman of Alpha Tau Medical. The company is strategically expanding its focus to include treatments for internal organ tumors.